These findings supported previous studies by Oridate et al. [33] and Dong et al. [19], who reported that decreased eIF4E could synergize cisplatin to suppress tumor cell growth by enhancing chemosenstivity in head and neck carcinoma and breast cancer. This evidence concerns the gene EIF4E and breast cancer.